Journal of Multiple Sclerosis

Biography

a native of St. Louis, practices neurology at Missouri Baptist Medical Center in St. Louis and is the director of The MS Center for Innovations in Care. He remains in the BJC Medical Group and on staff at Barnes-Jewish Hospital in St. Louis where he practiced full-time from 1999 to 2008. Dr. Singer graduated college from Duke University in 1988 and medical school from Columbia University in 1992. His neurology residency was at Cornell-New York Hospital and his two-year multiple sclerosis fellowship was at the National Institutes of Health. He has been an investigator in more than 20 clinical trials focused on new multiple sclerosis treatment options since 1994. He continues to publish in the field of multiple sclerosis and has served as course director for national continuing education programs. As a leader in multiple sclerosis and patient advocate, he has given lectures on MS throughout the U.S. and internationally.

Research Interest

Multiple sclerosis (MS) is the most common cause of neurologic disability in young adults, and it exhibits significant clinical, radiologic, and pathologic heterogeneity. MS remains a complex disease to manage, and no curative therapy exists. Furthermore, much debate remains about what few, available treatments should be enlisted, as well as when and for how long. Some issues, such as neutralizing antibodies to interferon-beta, one of the mainstays of MS treatment, have emerged as a clinical controversy in the field. Scott Williams, Senior Editor, Medscape Neurology & Neurosurgery, interviewed Barry Singer, MD, Assistant Professor of Clinical Neurology at Washington University School of Medicine in St. Louis, Missouri, to discuss these and other important issues in the management of patients with MS, including new research presented at the 56th Annual Meeting of the American Academy of Neurology.

Relevant Topics